AI

Copyright © 2026 LexisNexis

This subtopic contains guidance on EU-level rules relating to artificial intelligence (AI).

‘Artificial intelligence’ refers to systems that are designed to perform in human-like ways. They may, for example, mimic the human ability to perceive, analyse, learn, reason and deduce. The term AI encompasses such computing concepts as machine learning (ML), speech and natural language processing, robotics and autonomous systems. Practice Note: Artificial intelligence—glossary of terms for legal professionals provides a glossary of key terms and concepts designed to provide legal professionals with a better understanding of key AI concepts.

One of the reasons why AI has generated so much interest in the EU, is that it is a non-specific technology and can be applied to a range of uses in a multitude of sectors.

For a complete list of resources covering AI, see Practice Note: Artificial intelligence (AI) resource kit.

Tracking developments

For the most important updates relating to legal issues surrounding the development of AI in the EU, see Practice Notes:

  1. •

    EU artificial intelligence—horizon scanner which tracks key future developments in EU AI law. It provides details of key dates for your diary

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Existing user? Sign-in TAKE A FREE TRIAL
Powered by Lexis+®
Latest EU Law News

EU Financial Services—daily round-up (13 March 2026)

A round-up of EU financial services developments.

Council of the EU agrees position on  EU AI Act streamlining proposal

The Council of the European Union has agreed its position on a proposal to simplify the implementation of harmonised rules on artificial intelligence (AI) under the EU AI Act, as part of the Digital Omnibus within the EU’s broader simplification agenda. The proposal aims to streamline requirements, reduce administrative burdens and ensure more proportionate and harmonised application of AI rules across Member States.

Commission and EDPB publish responses to consultation on draft EU DMA-GDPR joint guidelines

The European Commission and the European Data Protection Board (EDPB) have published the submissions received in response to their October 2025 consultation on draft joint guidelines addressing the interplay between the EU Digital Markets Act (DMA) and Regulation (EU) 2016/679 (General Data Protection Regulation (GDPR)). More than 100 contributions were submitted, reflecting broad support among respondents for the initiative and for enhanced cross-regulatory dialogue. The Commission and the EDPB are currently reviewing the submissions to determine whether and how to adapt the draft joint guidelines, with the final guidelines expected to be adopted in Q4 2026. The guidelines are intended to improve legal clarity and certainty for businesses and citizens in the EU, while ensuring consistency between DMA enforcement and the protection of fundamental rights under the GDPR.

EFPIA reports on IHI public-private partnership project launches

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has reported on the launch of several projects under the Innovative Health Initiative (IHI), outlining their funding allocations and project objectives. Under IHI Call 8, four projects received combined funding of €95.7m. These include Cities@Heart (€28.5m in total funding to support cardiovascular disease prevention in urban areas), BRIDGE (€9.5m to develop a regulatory sandbox framework), UNIFIED (€26.2m to develop patient-centred clinical endpoints) and PROBE (€31.5m to improve knee osteoarthritis care through big data approaches). Under IHI Call 9, thirteen proposals were selected for funding across various health research areas, with nine projects already having commenced. Notable projects include LIGAND-AI, which received €62.6m to accelerate drug development using artificial intelligence (AI), GUIDE-AI (€9.1m to develop AI-powered clinical guideline tools for chronic diseases) and END2AMR (€30m to support the development of treatments for drug-resistant infections). The funding comprises a combination of EU contributions and industry and partner investments. These initiatives are intended to address priority health challenges, with most projects expected to be completed by 2030.

View EU Law by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements[Insert addressee details]Dear [insert name][It is our understanding that [insert name of prospective employee] [was an employee of yours between the dates of [insert dates as appropriate] OR is a current employee of
What is the difference between an appeal and a review?

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements[Insert addressee details]Dear [insert name][It is our understanding that [insert name of prospective employee] [was an employee of yours between the dates of [insert dates as appropriate] OR is a current employee of